Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2026)

Journey Medical's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $91.5 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 7.74% year-over-year to $91.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $352.5 million (up 19.71% YoY) and the FY2025 annual result came in at $94.6 million, up 17.88% from the prior year.
• Liabilities and Shareholders Equity was $91.5 million for Q1 2026 at Journey Medical, down from $94.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $120.9 million in Q1 2022 and bottomed at $64.0 million in Q3 2024.
• A 5-year average of $86.4 million and a median of $85.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 39.05% — and 2025, when it surged 33.02%.
• Journey Medical's Liabilities and Shareholders Equity stood at $105.2 million in 2022, then declined by 26.92% to $76.8 million in 2023, then gained by 4.41% to $80.2 million in 2024, then grew by 17.88% to $94.6 million in 2025, then fell by 3.23% to $91.5 million in 2026.
• Business Quant data shows DERM's Liabilities and Shareholders Equity at $91.5 million in Q1 2026, $94.6 million in Q4 2025, and $85.2 million in Q3 2025.